Insider Trading March 4, 2026

Ceribell CTO Sells $202K in Stock, Exercises Options as Company Advances LVO Stroke Monitor

Raymond Woo both sold and exercised shares on March 2, 2026; Ceribell posts regulatory and corporate updates amid a 42% six-month rally

By Avery Klein CBLL
Ceribell CTO Sells $202K in Stock, Exercises Options as Company Advances LVO Stroke Monitor
CBLL

Ceribell, Inc.'s Chief Technology Officer Raymond Woo executed a sale and an option exercise on March 2, 2026, selling 11,112 shares for roughly $202,838 while simultaneously acquiring 11,112 shares via option exercises for $48,605. The company's shares have risen 42% over six months and trade below Woo's sale price. Ceribell also received FDA Breakthrough Device Designation for an LVO stroke detection monitor, saw BTIG reaffirm a Buy rating with a $30 price target, recorded a board resignation effective December 31, 2025, and extended Sunnyvale office leases through January 2028.

Key Points

  • CTO Raymond Woo sold 11,112 shares on March 2, 2026 for about $202,838 at a weighted average price of $18.25 to $18.26 while also exercising options to acquire 11,112 shares at a total cost of $48,605.
  • Ceribell received FDA Breakthrough Device Designation for an LVO stroke detection monitor that pairs existing EEG hardware with an AI algorithm; if cleared, it could be the first point-of-care technology for LVO detection.
  • BTIG reaffirmed a Buy rating with a $30 price target and highlighted near 30% projected growth for 2026; the company also extended its Sunnyvale office lease through January 2028 with monthly rent of $34,821.

Ceribell, Inc. (CBLL) disclosed insider activity involving its Chief Technology Officer, Raymond Woo. On March 2, 2026, Woo sold 11,112 shares of the company's common stock for approximately $202,838. The shares were sold at a weighted average price between $18.25 and $18.26.

The company’s stock was trading at $17.77 at the time this report was compiled, which is modestly below the price realized by Woo in the transaction. Ceribell's market capitalization stood at $660.23 million.

On the same trading day, Woo acquired an identical number of shares - 11,112 - through the exercise of options. The exercise prices for those options ranged from $2.24 to $4.70, and the aggregate cost to Woo for the exercised options was $48,605.

Over the prior six months, CBLL shares had climbed roughly 42%. An analysis from InvestingPro cited in company commentary suggests the stock may be overvalued at current levels. The InvestingPro note referenced the availability of eight additional ProTips for subscribers, which reportedly include commentary on Ceribell's financial condition and profitability outlook.


Separately, Ceribell announced that it has secured FDA Breakthrough Device Designation for a Large Vessel Occlusion (LVO) stroke detection monitor. The device combines existing electroencephalography (EEG) hardware with an AI-based algorithm designed to identify LVO strokes early in hospital settings. If the device receives final regulatory clearance, it could become the first point-of-care technology for LVO detection.

In coverage developments, brokerage BTIG reaffirmed its Buy rating on Ceribell and maintained a $30 price target while highlighting an expected growth rate of nearly 30% for 2026.

Corporate governance activity included the resignation of director Lucian Iancovici from Ceribell’s board of directors, effective December 31, 2025. The company reported that the resignation occurred with no disagreements regarding the company’s operations or policies.

On the real estate and operations front, Ceribell extended its office leases in Sunnyvale, California. The extension runs through January 2028 and covers approximately 11,607 square feet, with a monthly rent of $34,821.

Taken together, the insider transactions, regulatory milestone, broker commentary, board change, and lease extension outline a series of operational and financial developments for Ceribell as the company advances its LVO detection technology and manages ongoing corporate requirements.

Risks

  • Regulatory uncertainty - the LVO stroke detection monitor is designated as a Breakthrough Device, but final market clearance is not guaranteed; regulatory outcome will affect commercialization and adoption in healthcare settings.
  • Valuation concerns - InvestingPro analysis suggests CBLL may be overvalued at current prices, introducing market risk for investors in the healthcare and medtech sectors.
  • Operating cost commitments - the extended Sunnyvale lease creates ongoing cash obligations that could affect Ceribell's operating expenses and real estate exposure.

More from Insider Trading

Old Republic Director John Eric Smith Purchases $48,916 of ORI Stock Mar 4, 2026 Community West Bancshares EVP Purchases $5,492 in Stock; Company Reports Strong Quarter and Several Leadership Exits Mar 4, 2026 Community West Bancshares President Acquires $5,823 Stake; Company Posts Strong Q4 Earnings and Several Executive Retirements Mar 4, 2026 Community West Bancshares EVP Acquires Shares Via ESPP as Company Reports Strong Q4 2025 Results Mar 4, 2026 Community West Bancshares CEO Adds 1,089 Shares via ESPP in February Purchase Mar 4, 2026